MOSCOW (Reuters) – Russia’s sovereign fund said Friday that it had agreed to up to 35 million doses of russia’s experimental COVID-19 vaccine to Laxisam, an Uzbek pharmaceutical company.
The agreement is one of several agreements made through the Russian Direct Investment Fund (DRIF) in recent weeks to deliver the vaccine, which is recently being tested in a large-scale trial in Moscow, abroad.
It has also signed agreements with Kazakhstan, India, Mexico and two Brazilian states.
(Reporting through Anastasia Teterevleva; written through Polina Ivanova; edited through Alex Richardson)